Haloperidol for Pain Control in Patients With Acute Musculoskeletal Back Pain in the Emergency Department
Western Michigan University School of Medicine
75 participants
Jul 9, 2024
INTERVENTIONAL
Conditions
Summary
Single center, double-blind, randomized, controlled trial in patients who present to the emergency department (ED) with a chief complaint of back pain. A total of 150 patients age 18-65 presenting to the emergency department with chief complaint of backpain will be enrolled from April 2024 - April 2025. Patients will be randomized and symptom levels will be recorded at 30, 60, 90, minutes. Follow-up will be performed by telephone at 24 hours.
Eligibility
Inclusion Criteria3
- Age 18 - 65 years old
- Presenting to the Bronson ED with a chief complaint of acute, non-traumatic back pain
- VAS score >5 cm
Exclusion Criteria15
- Back pain due to traumatic injury
- Experiencing saddle anesthesia
- Has bowel or bladder dysfunction
- Has an abnormal neurological exam
- Requires imaging in ED
- Has a Glascow coma score <15
- Has one or more abnormal vital signs:
- HR>120, SBP>180 or <90, temperature >38°, O2 saturation<92%
- Has an allergy to ketorolac or haloperidol
- Has a known diagnosis of Lewy Body Dementia
- Has a known diagnosis of glaucoma.
- Is known to be pregnant or breastfeeding
- Is a prisoner or ward of the state
- Is unable to consent for themselves/ non-english speaking
- In the opinion of the attending physician or investigator the patient should not participate in the research
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Intramuscular injection of drug
Intramuscular injection of drug
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06395428